Pulmonary function alterations after induction therapy for lung cancer: Preoperative considerations

Gabriel Loor; Mark K. Ferguson

doi:10.1007/978-1-84996-492-0_10

Pulmonary function alterations after induction therapy for lung cancer: Preoperative considerations

Gabriel Loor, Mark K. Ferguson

Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery offers hope for extended survival in patients with regionally advanced non-small cell lung cancer (NSCLC), particularly those patients with ipsilateral mediastinal nodal involvement. However, neoadjuvant therapies are sometimes associated with pulmonary toxicity. A recent large scale analysis using the Society of Thoracic Surgery (STS) General Thoracic Surgery Database identified induction therapy as an independent predictor of postoperative pulmonary complications.1 The present chapter reviews the effects of neoadjuvant therapy on pulmonary function as well as perioperative morbidity and mortality, and examines whether altering the timing of resection can reduce the risk of complications.

Original language	English (US)
Title of host publication	Difficult Decisions in Thoracic Surgery (Second Edition)
Subtitle of host publication	An Evidence-Based Approach
Publisher	Springer London
Pages	105-110
Number of pages	6
ISBN (Print)	9781849963640
DOIs	https://doi.org/10.1007/978-1-84996-492-0_10
State	Published - Dec 1 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/978-1-84996-492-0_10

Find It

Find It at U of M Libraries

Cite this

@inbook{aceac926b0464710a6600a2f111ee5cd,

title = "Pulmonary function alterations after induction therapy for lung cancer: Preoperative considerations",

abstract = "Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery offers hope for extended survival in patients with regionally advanced non-small cell lung cancer (NSCLC), particularly those patients with ipsilateral mediastinal nodal involvement. However, neoadjuvant therapies are sometimes associated with pulmonary toxicity. A recent large scale analysis using the Society of Thoracic Surgery (STS) General Thoracic Surgery Database identified induction therapy as an independent predictor of postoperative pulmonary complications.1 The present chapter reviews the effects of neoadjuvant therapy on pulmonary function as well as perioperative morbidity and mortality, and examines whether altering the timing of resection can reduce the risk of complications.",

author = "Gabriel Loor and Ferguson, {Mark K.}",

year = "2011",

month = dec,

day = "1",

doi = "10.1007/978-1-84996-492-0_10",

language = "English (US)",

isbn = "9781849963640",

pages = "105--110",

booktitle = "Difficult Decisions in Thoracic Surgery (Second Edition)",

publisher = "Springer London",

address = "United Kingdom",

}

TY - CHAP

T1 - Pulmonary function alterations after induction therapy for lung cancer

T2 - Preoperative considerations

AU - Loor, Gabriel

AU - Ferguson, Mark K.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery offers hope for extended survival in patients with regionally advanced non-small cell lung cancer (NSCLC), particularly those patients with ipsilateral mediastinal nodal involvement. However, neoadjuvant therapies are sometimes associated with pulmonary toxicity. A recent large scale analysis using the Society of Thoracic Surgery (STS) General Thoracic Surgery Database identified induction therapy as an independent predictor of postoperative pulmonary complications.1 The present chapter reviews the effects of neoadjuvant therapy on pulmonary function as well as perioperative morbidity and mortality, and examines whether altering the timing of resection can reduce the risk of complications.

AB - Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery offers hope for extended survival in patients with regionally advanced non-small cell lung cancer (NSCLC), particularly those patients with ipsilateral mediastinal nodal involvement. However, neoadjuvant therapies are sometimes associated with pulmonary toxicity. A recent large scale analysis using the Society of Thoracic Surgery (STS) General Thoracic Surgery Database identified induction therapy as an independent predictor of postoperative pulmonary complications.1 The present chapter reviews the effects of neoadjuvant therapy on pulmonary function as well as perioperative morbidity and mortality, and examines whether altering the timing of resection can reduce the risk of complications.

UR - http://www.scopus.com/inward/record.url?scp=84890007697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890007697&partnerID=8YFLogxK

U2 - 10.1007/978-1-84996-492-0_10

DO - 10.1007/978-1-84996-492-0_10

M3 - Chapter

AN - SCOPUS:84890007697

SN - 9781849963640

SP - 105

EP - 110

BT - Difficult Decisions in Thoracic Surgery (Second Edition)

PB - Springer London

ER -

Pulmonary function alterations after induction therapy for lung cancer: Preoperative considerations

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this